Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

被引:898
作者
Feldman, Morris E. [1 ,2 ]
Apsel, Beth [1 ,2 ]
Uotila, Aino [3 ]
Loewith, Robbie [3 ]
Knight, Zachary A. [1 ,2 ]
Ruggero, Davide [4 ,5 ]
Shokat, Kevan M. [1 ,2 ]
机构
[1] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA
[3] Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland
[4] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA 94143 USA
关键词
INTEGRIN-LINKED KINASE; PHAS-I; MAMMALIAN TARGET; MOTIF PHOSPHORYLATION; AKT PHOSPHORYLATION; BINDING PARTNER; (S/T)P SITES; AMINO-ACIDS; RICTOR; INSULIN;
D O I
10.1371/journal.pbio.1000038
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mammalian target of rapamycin (mTOR) regulates cell growth and survival by integrating nutrient and hormonal signals. These signaling functions are distributed between at least two distinct mTOR protein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to the selective inhibitor rapamycin and activated by growth factor stimulation via the canonical phosphoinositide 3-kinase (PI3K)-> Akt -> mTOR pathway. Activated mTORC1 kinase up-regulates protein synthesis by phosphorylating key regulators of mRNA translation. By contrast, mTORC2 is resistant to rapamycin. Genetic studies have suggested that mTORC2 may phosphorylate Akt at S473, one of two phosphorylation sites required for Akt activation; this has been controversial, in part because RNA interference and gene knockouts produce distinct Akt phospho-isoforms. The central role of mTOR in controlling key cellular growth and survival pathways has sparked interest in discovering mTOR inhibitors that bind to the ATP site and therefore target both mTORC2 and mTORC1. We investigated mTOR signaling in cells and animals with two novel and specific mTOR kinase domain inhibitors (TORKinibs). Unlike rapamycin, these TORKinibs (PP242 and PP30) inhibit mTORC2, and we use them to show that pharmacological inhibition of mTOR blocks the phosphorylation of Akt at S473 and prevents its full activation. Furthermore, we show that TORKinibs inhibit proliferation of primary cells more completely than rapamycin. Surprisingly, we find that mTORC2 is not the basis for this enhanced activity, and we show that the TORKinib PP242 is a more effective mTORC1 inhibitor than rapamycin. Importantly, at the molecular level, PP242 inhibits cap-dependent translation under conditions in which rapamycin has no effect. Our findings identify new functional features of mTORC1 that are resistant to rapamycin but are effectively targeted by TORKinibs. These potent new pharmacological agents complement rapamycin in the study of mTOR and its role in normal physiology and human disease.
引用
收藏
页码:371 / 383
页数:13
相关论文
共 56 条
  • [1] Role of translocation in the activation and function of protein kinase B
    Andjelkovic, M
    Alessi, DR
    Meier, R
    Fernandez, A
    Lamb, NJC
    Frech, M
    Cron, P
    Cohen, P
    Lucocq, JM
    Hemmings, BA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (50) : 31515 - 31524
  • [2] Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
    Apsel, Beth
    Blair, Jimmy A.
    Gonzalez, Beatriz
    Nazif, Tamim M.
    Feldman, Morri E.
    Aizenstein, Brian
    Hoffman, Randy
    Williams, Roger L.
    Shokat, Kevan M.
    Knight, Zachary A.
    [J]. NATURE CHEMICAL BIOLOGY, 2008, 4 (11) : 691 - 699
  • [3] When translation meets transformation: the mTOR story
    Averous, J.
    Proud, C. G.
    [J]. ONCOGENE, 2006, 25 (48) : 6423 - 6435
  • [4] PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival
    Bozulic, Lana
    Surucu, Banu
    Hynx, Debby
    Hemmings, Brian A.
    [J]. MOLECULAR CELL, 2008, 30 (02) : 203 - 213
  • [5] Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002
    Brunn, GJ
    Williams, J
    Sabers, C
    Wiederrecht, G
    Lawrence, JC
    Abraham, RT
    [J]. EMBO JOURNAL, 1996, 15 (19) : 5256 - 5267
  • [6] Targeting the mTOR signaling network in cancer
    Chiang, Gary G.
    Abraham, Robert T.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2007, 13 (10) : 433 - 442
  • [7] mTOR and cancer therapy
    Easton, J. B.
    Houghton, P. J.
    [J]. ONCOGENE, 2006, 25 (48) : 6436 - 6446
  • [8] Fadden P, 1997, J BIOL CHEM, V272, P10240
  • [9] Current development of mTOR inhibitors as anticancer agents
    Faivre, Sandrine
    Kroemer, Guido
    Raymond, Eric
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) : 671 - 688
  • [10] Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1
    Feldman, RI
    Wu, JM
    Polokoff, MA
    Kochanny, MJ
    Dinter, H
    Zhu, DG
    Biroc, SL
    Alicke, B
    Bryant, J
    Yuan, SD
    Buckman, BO
    Lentz, D
    Ferrer, M
    Whitlow, M
    Adler, M
    Finster, S
    Chang, Z
    Arnaiz, DO
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (20) : 19867 - 19874